{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T08:29:59Z","timestamp":1781857799365,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>This study was to compare radiotherapy treatment planning and treatment outcomes following three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT) in stage I-II natural killer (NK)\/T-cell lymphoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The cases of 94 patients with stage I-II NK\/T-cell lymphoma, nasal type in the upper aerodigestive tract who treated between May 2005 and Dec 2008 were reviewed. These patients received radiotherapy with or without induction chemotherapy. Definitive radiotherapy was conducted using 3DCRT in 47 patients and IMRT in the other 47 patients with a regional field and a total dose of 50 Gy. Dosimetric pmeters of radiation treatment plans, local control probability (LCP), overall survival (OS), and toxicities were analyzed and compared between 3DCRT and IMRT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>From the dosimetric analysis, IMRT demonstrated significantly better dose coverage and homogeneity than 3DCRT. However, after a median follow-up of 46 months, IMRT was not associated with improvements in 4y-OS (80.9% for 3DCRT vs. 82.7% for IMRT, <jats:italic>p<\/jats:italic>=0.87) or 4y-LCP (86.3% for 3DCRT vs. 88.9% for IMR <jats:italic>p<\/jats:italic>=0.85). Of the 18 patients who received cervical lymph node irradiation, those in the IMRT group received a lower mean parotid dose. Furthermore, at-risk organs were strictly kept within the safe dose range in both groups, and no severe late toxicity was observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>IMRT provided better dose coverage than 3DCRT, although it failed to provide LCP and OS benefits. Definitive radiotherapy with a regional field and a total dose of 50 Gy is efficient and safe for NK\/T-cell lymphoma using either IMRT or 3DCRT. However, IMRT may have the potential to reduce parotid gland hypofunction following cervical irradiation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1748-717x-8-152","type":"journal-article","created":{"date-parts":[[2013,6,25]],"date-time":"2013-06-25T06:15:18Z","timestamp":1372140918000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for stage I-II natural killer\/T-cell lymphoma nasal type: dosimetric and clinical results"],"prefix":"10.1186","volume":"8","author":[{"given":"Qianwen","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weigang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanfei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,25]]},"reference":[{"key":"907_CR1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"NL Harris","year":"1994","unstructured":"Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European\u2013American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 1994, 84: 1361-1392.","journal-title":"Blood"},{"key":"907_CR2","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.1995.13.3.666","volume":"13","author":"R Liang","year":"1995","unstructured":"Liang R, Todd D, Chan TK, Chiu E, Lie A, Kwong YL, Choy D, Ho FC: Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol 1995, 13: 666-670.","journal-title":"J Clin Oncol"},{"key":"907_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/00000478-199601000-00012","volume":"20","author":"ES Jaffe","year":"1996","unstructured":"Jaffe ES, Chan JK, Su IJ, Frizzera G, Mori S, Feller AC, Ho FC: Report of the workshop on nasal and related extranodal angiocentric T\/natural killer cell lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996, 20: 103-111. 10.1097\/00000478-199601000-00012","journal-title":"Am J Surg Pathol"},{"key":"907_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.radonc.2009.08.045","volume":"93","author":"X Ma","year":"2009","unstructured":"Ma X, Guo Y, Pang Z, Wang B, Lu H, Gu YJ, Guo X: A randomized phase II study of CEOP with or without semustine as induction chemotherapy in patients with stage IE\/IIE extranodal NK\/T-cell lymphoma, nasal type in the upper aerodigestive tract. Radiother Oncol 2009, 93: 492-497. 10.1016\/j.radonc.2009.08.045","journal-title":"Radiother Oncol"},{"key":"907_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1200\/JCO.2005.03.2573","volume":"24","author":"YX Li","year":"2006","unstructured":"Li YX, Yao B, Jin J, Wang WH, Liu YP, Song YW, Wang SL, Liu XF, Zhou LQ, He XH, Lu N, Yu ZH: Radiotherapy as primary treatment for stage IE and IIE nasal natural killer\/T-cell lymphoma. J Clin Oncol 2006, 24: 181-189. 10.1200\/JCO.2005.03.2573","journal-title":"J Clin Oncol"},{"key":"907_CR6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/cncr.11908","volume":"100","author":"CC Li","year":"2004","unstructured":"Li CC, Tien HF, Tang JL, Yao M, Chen YC, Su IJ, Hsu SM, Hong RL: Treatment outcome and pattern of failure in 77 patients with sinonasal natural kill\/T-cell or T-cell lymphoma. Cancer 2004, 100: 366-375. 10.1002\/cncr.11908","journal-title":"Cancer"},{"key":"907_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/cncr.21656","volume":"106","author":"K Isobe","year":"2006","unstructured":"Isobe K, Uno T, Tamaru J, Kawakami H, Ueno N, Wakita H, Okada J, Itami J, Ito H: Extranodal natural killer\/T-cell lymphoma, nasal type the significance of radiotherapeutic pmeters. Cancer 2006, 106: 609-615. 10.1002\/cncr.21656","journal-title":"Cancer"},{"key":"907_CR8","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1200\/JCO.2000.18.1.54","volume":"18","author":"GE Kim","year":"2000","unstructured":"Kim GE, Cho JH, Yang WI, Chung EJ, Suh CO, Park KR, Hong WP, Park IY, Hahn JS, Roh JK, Kim BS: A ngiocentric lymphoma of the head and neck: patterns of systemic failure after radiation therapy. J Clin Oncol 2000, 18: 54-63.","journal-title":"J Clin Oncol"},{"key":"907_CR9","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.ijrobp.2003.12.006","volume":"59","author":"WS Koom","year":"2004","unstructured":"Koom WS, Chung EJ, Yang WI, Shim SJ, Suh CO, Roh JK, Yoon JH, Kim GE: Angiocentric T-cell and NK\/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys 2004, 59: 1127-1137. 10.1016\/j.ijrobp.2003.12.006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"907_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0936-6555(05)80974-4","volume":"4","author":"S Senan","year":"1992","unstructured":"Senan S, Symonds RP, Brown IL: Nasal peripheral T-cell lymphoma: a 20-year review of cases treated in Scotland. Clin Oncol 1992, 4: 96-100. 10.1016\/S0936-6555(05)80974-4","journal-title":"Clin Oncol"},{"key":"907_CR11","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.ijrobp.2011.02.039","volume":"82","author":"H Wang","year":"2012","unstructured":"Wang H, Li YX, Wang WH, Jin J, Dai JR, Wang SL, Liu YP, Song YW, Wang ZY, Liu QF, Fang H, Qi SN, Liu XF, Yu ZH: Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK\/T-cell lymphoma. Int J Radiat Oncol Biol Phys 2012, 82: 1115-1121. 10.1016\/j.ijrobp.2011.02.039","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"907_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1470-2045(10)70290-4","volume":"12","author":"CM Nutting","year":"2011","unstructured":"Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK, A'Hern RP, Sydenham MA, Emson M, Hall E: Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011, 12: 127-136. 10.1016\/S1470-2045(10)70290-4","journal-title":"Lancet Oncol"},{"key":"907_CR13","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1200\/JCO.2005.04.7225","volume":"24","author":"WM Mendenhall","year":"2006","unstructured":"Mendenhall WM, Amdur RJ, Palta JR: Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J Clin Oncol 2006, 24: 2618-2623. 10.1200\/JCO.2005.04.7225","journal-title":"J Clin Oncol"},{"key":"907_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0167-8140(01)00449-2","volume":"61","author":"KS Chao","year":"2001","unstructured":"Chao KS, Majhail N, Huang CJ, Simpson JR, Perez CA, Haughey B, Spector G: Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol 2001, 61: 275-280. 10.1016\/S0167-8140(01)00449-2","journal-title":"Radiother Oncol"},{"key":"907_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.radonc.2004.06.005","volume":"73","author":"PM Teo","year":"2004","unstructured":"Teo PM, Ma BB, Chan AT: Radiotherapy for nasopharyngeal carcinoma\u2013transition from two-dimensional to three-dimensional methods. Radiother Oncol 2004, 73: 163-172. 10.1016\/j.radonc.2004.06.005","journal-title":"Radiother Oncol"},{"key":"907_CR16","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1259\/bjr\/83758373","volume":"82","author":"N Tomita","year":"2009","unstructured":"Tomita N, Kodaira T, Tachibana H, Nakamura T, Nakahara R, Inokuchi H, Mizoguchi N, Takada A: A comparison of radiation treatment plans using IMRT with helical tomotherapy and 3D conformal radiotherapy for nasal natural killer\/T-cell lymphoma. Br J Radiol 2009, 82: 756-763. 10.1259\/bjr\/83758373","journal-title":"Br J Radiol"},{"issue":"Suppl 3","key":"907_CR17","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.ijrobp.2009.07.1754","volume":"76","author":"LB Marks","year":"2010","unstructured":"Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, Bentzen SM, Nam J, Deasy JO: Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010,76(Suppl 3):S10-S19.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"907_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ijrobp.2005.09.028","volume":"64","author":"L Feuvret","year":"2006","unstructured":"Feuvret L, No\u00ebl G, Mazeron JJ, Bey P: Conformity index: a review. Int J Radiat Oncol Biol Phys 2006, 64: 333-342. 10.1016\/j.ijrobp.2005.09.028","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"907_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00066-011-0015-x","volume":"188","author":"N Hodapp","year":"2012","unstructured":"Hodapp N: The ICRU report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT). Strahlenther Onkol 2012, 188: 97-99. 10.1007\/s00066-011-0015-x","journal-title":"Strahlenther Onkol"},{"key":"907_CR20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V: Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25: 579-586. 10.1200\/JCO.2006.09.2403","journal-title":"J Clin Oncol"},{"key":"907_CR21","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ctrv.2011.01.004","volume":"37","author":"S Tribius","year":"2011","unstructured":"Tribius S, Bergelt C: Intensity-modulated radiotherapy versus conventional and 3D conformal radiotherapy in patients with head and neck cancer: is there a worthwhile quality of life gain? Cancer Treat Rev 2011, 37: 511-519. 10.1016\/j.ctrv.2011.01.004","journal-title":"Cancer Treat Rev"},{"key":"907_CR22","doi-asserted-by":"publisher","first-page":"5594","DOI":"10.1200\/JCO.2009.23.8295","volume":"27","author":"M Yamaguchi","year":"2009","unstructured":"Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Ohshima K, Matsuno Y, Terauchi T, Nawano S, Ishikura S, Kagami Y, Hotta T, Oshimi K: Phase I\/II study of concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: Japan clinical oncology group study JCOG0211. J Clin Oncol 2009, 27: 5594-5600. 10.1200\/JCO.2009.23.8295","journal-title":"J Clin Oncol"},{"key":"907_CR23","doi-asserted-by":"publisher","first-page":"6027","DOI":"10.1200\/JCO.2009.23.8592","volume":"27","author":"SJ Kim","year":"2009","unstructured":"Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, Ahn YC, Ko YH, Kim WS: Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK\/T-cell lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol 2009, 27: 6027-6032. 10.1200\/JCO.2009.23.8592","journal-title":"J Clin Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1748-717X-8-152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:45:49Z","timestamp":1630543549000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/1748-717X-8-152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,25]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["907"],"URL":"https:\/\/doi.org\/10.1186\/1748-717x-8-152","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,25]]},"assertion":[{"value":"4 February 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"152"}}